<img alt="" src="https://secure.wake4tidy.com/244317.png" style="display:none;">

Vironova´s CEO Mohammed Homman on OXY Talks

Video from last weeks OXY Talks where Vironova's CEO and founder Mohammed Homman shares his entrepreneurial journey with Susanna Balsvik and Emma Vallin from OXY Group. Who together from different views and experiences explore the challenges and...


Mohammed Homman CEO at Vironova AB awarded the "Top Talents Creator Award" by SwedenBIO

September 15, 2021 We are delighted and honored for the recognition we got at SwedenBIO´s Executive Dinner and BIO-Gala, where our CEO Mohammed Homman received the “Top Talent Creator Award” on behalf of Vironova. An award given to those creating...


Annual General Meeting 2021 - Vironova AB

Shareholders of Vironova AB (publ), 556678-1463, are hereby summoned to our annual general meeting which will be held on June 30, 2021.


Collaboration between National Physical Laboratory (NPL) and Vironova to empower the UK life science industry

April 28, 2021 NPL’s Biometrology laboratory will further increase their electron microscopy capabilities by hosting Vironova’s MiniTEM system through a new partnership between the organizations.


AI research for automated microscopy imaging and processing

Together with leading microscopy image processing researchers at Uppsala University, Vironova has recently published a new peer reviewed research article in the area of microscopy imaging and processing. The article investigates if and how some of...


New collaboration with SwedenBIO to develop the life science industry

Vironova’s Director Human Resources, Ann Fredriksson, will be one of a handful members of a new task force put together by SwedenBIO. The cross-organizational group will focus on finding solutions to current human resource challenges in the Nordic...


Vironova Medical AB in development of SARS-CoV-2 antiviral drugs

Vironova Medical AB, a spin off from Vironova AB, have developed an antiviral drug candidate against SARS-CoV-2. A novel class of antiviral drugs against covid-19/SARS-CoV-2, first evaluated in vitro against SARS-CoV-2 virus at the University of...


Vironova is part of the MAD-CoV 2 project

The SARS-CoV-2 pandemic has had a significant negative impact on the world’s public health and the global economy since its outbreak in the beginning of 2020. From this has the international MAD-CoV 2 project emerged, trying to provide an increased...


Vironova in ​strategic collaboration with a top-tier consultancy

Stockholm, 1st of December 2020. A message from our CEO, Mohammed Homman. I am very pleased to announce a new strategic partnership between Vironova and a top-tier management consultancy1, focusing on accelerating Vironova’s growth and valuation.


The TEMperature with our R&D team

Congratulations from all Vironovians, and especially from our R&D team to our collaborators in the HASTE team, winning the AI cell analysis challenge organized by AI Sweden AI Sweden and AstraZeneca in fierce international competition!